These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32884532)

  • 1. Eltrombopag Use for Treatment of Thrombocytopenia in a Patient with Chronic Liver Disease and Portal Vein Thrombosis: Case Report.
    Mohamed SE; Yassin MA
    Case Rep Oncol; 2020; 13(2):863-866. PubMed ID: 32884532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Portal vein thrombosis during eltrombopag treatment for immune thrombocytopenic purpura in a patient with liver cirrhosis due to hepatitis C viral infection.
    Kawano N; Hasuike S; Iwakiri H; Nakamura K; Ozono Y; Kusumoto H; Nagata K; Kikuchi I; Yoshida S; Kuriyama T; Yamashita K; Muranaka T; Kawaguchi T; Sata M; Okamura T; Ueda A; Shimoda K
    J Clin Exp Hematop; 2013; 53(2):151-5. PubMed ID: 23995112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis.
    Loffredo L; Violi F
    Dig Liver Dis; 2019 Jan; 51(1):24-27. PubMed ID: 29958825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe thrombocytopenia in a patient with hepatitis C treated with eltrombopag from off-label drug use to on-label drug use: a case report.
    Al-Jafar HA; Al-Khaldi J; Alduaij A; Al-Banwan K
    J Med Case Rep; 2014 Sep; 8():303. PubMed ID: 25209590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence.
    Qureshi K; Patel S; Meillier A
    Int J Hepatol; 2016; 2016():1802932. PubMed ID: 27800187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Portal Vein Thrombosis During Eltrombopag Treatment Concomitant Splenectomy for Immune Thrombocytopenia.
    Saito M; Morioka M; Izumiyama K; Mori A; Kondo T
    Cureus; 2021 Aug; 13(8):e17478. PubMed ID: 34589366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
    N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia.
    Danish FI; Yasmin S
    Hepat Med; 2013; 5():17-30. PubMed ID: 24696622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
    Aguilar C
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):231-6. PubMed ID: 23518832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
    Kawaguchi T; Komori A; Seike M; Fujiyama S; Watanabe H; Tanaka M; Sakisaka S; Nakamuta M; Sasaki Y; Oketani M; Hattori T; Katsura K; Sata M
    J Gastroenterol; 2012 Dec; 47(12):1342-51. PubMed ID: 22674141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
    Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
    Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
    Gao Y; Gong M; Zhang C; Kong X; Ma Y
    Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.
    Tarantino MD; Bakshi KK; Brainsky A
    Platelets; 2014; 25(1):55-61. PubMed ID: 23402314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag in chronic hepatitis C.
    Mihăilă RG; Cipăian RC
    World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study.
    Nomoto H; Morimoto N; Miura K; Watanabe S; Takaoka Y; Maeda H; Sasaki T; Koyashiki Y; Kurata H; Numao N; Isoda N; Yamamoto H
    BMC Gastroenterol; 2020 Dec; 20(1):427. PubMed ID: 33317473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study.
    Ding JN; Feng TT; Sun W; Cai XY; Zhang Y; Zhao WF
    World J Gastrointest Surg; 2022 Nov; 14(11):1260-1271. PubMed ID: 36504518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.